Using oncolytic virus therapy, doctors are tapping into the body's immune response to treat cancer, showing promising results in initial clinical trials in humans.
A study inspired by the immune response to transplanted organs explored the safety and immunity of using modified Newcastle disease virus to target tumors.
Of the 23 patients in the clinical trial, the majority experienced tumor growth inhibition or shrinkage, highlighting the potential of the therapy.
The researchers' findings suggest that this modified virus could serve as an anti-tumor drug, warranting further trials to investigate its effects on more patients.
Collection
[
|
...
]